It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
COP1 and COP9 signalosome (CSN) are the substrate receptor and deneddylase of CRL4 E3 ligase, respectively. How they functionally interact remains unclear. Here, we uncover COP1–CSN antagonism during glucose-induced insulin secretion. Heterozygous Csn2WT/K70E mice with partially disrupted binding of IP6, a CSN cofactor, display congenital hyperinsulinism and insulin resistance. This is due to increased Cul4 neddylation, CRL4COP1 E3 assembly, and ubiquitylation of ETV5, an obesity-associated transcriptional suppressor of insulin secretion. Hyperglycemia reciprocally regulates CRL4-CSN versus CRL4COP1 assembly to promote ETV5 degradation. Excessive ETV5 degradation is a hallmark of Csn2WT/K70E, high-fat diet-treated, and ob/ob mice. The CRL neddylation inhibitor Pevonedistat/MLN4924 stabilizes ETV5 and remediates the hyperinsulinemia and obesity/diabetes phenotypes of these mice. These observations were extended to human islets and EndoC-βH1 cells. Thus, a CRL4COP1-ETV5 proteolytic checkpoint licensing GSIS is safeguarded by IP6-assisted CSN-COP1 competition. Deregulation of the IP6-CSN-CRL4COP1-ETV5 axis underlies hyperinsulinemia and can be intervened to reduce obesity and diabetic risk.
Mediators of insulin signalling are targets of cullin-RING ubiquitin ligases (CRL) that mediate protein degradation, but the role of protein degradation in insulin signalling is incompletely understood. Here, the authors identified a glucose-responsive CRL4-COP1-ETV5 proteolytic axis that promotes insulin secretion, and is inhibited under hypoglycemia.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Southern University of Science and Technology, Shenzhen, School of Life Sciences, Department of Biology, Guangdong, China (GRID:grid.263817.9)
2 Southern University of Science and Technology, Shenzhen, School of Life Sciences, Department of Biology, Guangdong, China (GRID:grid.263817.9); The University of Hong Kong, School of Biological Sciences, Pokfulam, Hong Kong (GRID:grid.194645.b) (ISNI:0000000121742757)
3 Technology, and Research, Singapore Bioimaging Consortium, Agency for Science, Singapore, Singapore (GRID:grid.185448.4) (ISNI:0000 0004 0637 0221)
4 the Third People’s Hospital of Shenzhen and the Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Department of Hepatic Surgery, Guangdong, China (GRID:grid.263817.9)
5 The University of Hong Kong, School of Biological Sciences, Pokfulam, Hong Kong (GRID:grid.194645.b) (ISNI:0000000121742757)
6 National Institute of Biological Sciences, Beijing, China (GRID:grid.410717.4) (ISNI:0000 0004 0644 5086)